GlobeNewswire: Sorrento Therapeutics, Inc. Contains the last 10 of 270 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T07:30:50ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2023/09/12/2741721/0/en/Sorrento-Announces-Phase-3-Trial-Met-Primary-Endpoint-and-Key-Secondary-Endpoint-in-Mild-or-Moderate-COVID-19-Adult-Patients-Treated-with-Ovydso-Olgotrelvir-an-Oral-Mpro-Inhibitor-.html?f=22&fvtc=4&fvtv=43606Sorrento Announces Phase 3 Trial Met Primary Endpoint and Key Secondary Endpoint in Mild or Moderate COVID-19 Adult Patients Treated with Ovydso (Olgotrelvir), an Oral Mpro Inhibitor as a Standalone Treatment for COVID-192023-09-12T13:00:00Z<![CDATA[SAN DIEGO, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (OTC: SRNEQ, “Sorrento”) announced today positive topline results of a pivotal Phase 3 study of Sorrento’s oral Mpro inhibitor, Ovydso (Olgotrelvir, STI-1558), in mild or moderate symptomatic adults infected with SARS-CoV-2, or COVID-19, irrespective of risk factors for severe complications. Ovydso is an Oral Mpro Inhibitor as a standalone treatment for COVID-19 meaning it does not require co-administration with other agents. The Phase 3 study results met the primary endpoint of time to sustained recovery of 11 COVID-19 symptoms, as well as the key second endpoint of the viral RNA copy load reduction at Day 4 (after three-day treatment).]]>https://www.globenewswire.com/news-release/2023/09/07/2739412/0/en/Sorrento-Therapeutics-Announces-Positive-Phase-2a-Clinical-Trial-Results-for-Resiniferatoxin-RTX-for-the-Treatment-of-Knee-Pain-in-Moderate-to-Severe-Osteoarthritis-of-the-Knee-OAK.html?f=22&fvtc=4&fvtv=43606Sorrento Therapeutics Announces Positive Phase 2a Clinical Trial Results for Resiniferatoxin (RTX) for the Treatment of Knee Pain in Moderate to Severe Osteoarthritis of the Knee (OAK) Patients2023-09-07T13:00:00Z<![CDATA[SAN DIEGO, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (OTC: SRNEQ, "Sorrento") announced today positive Phase 2a top-line clinical trial results for the RTX program.]]>Table 1Table 1Chart 1Chart 1Chart 2Chart 2Table 2Table 2https://www.globenewswire.com/news-release/2023/07/27/2712264/0/en/Sorrento-Issues-a-FAQ-in-Response-to-Large-Number-Of-Urgent-Requests-from-Scilex-Dividend-Short-Holders-and-or-Record-Holders.html?f=22&fvtc=4&fvtv=43606Sorrento Issues a “FAQ” in Response to Large Number Of Urgent Requests from Scilex Dividend Short Holders and/or Record Holders2023-07-27T13:00:00Z<![CDATA[SAN DIEGO, July 27, 2023 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (OTC: SRNEQ, "Sorrento"), a biopharmaceutical company dedicated to the development of life-saving therapeutics to treat cancer, intractable pain, and infectious disease, today announced that, in connection with its ongoing chapter 11 case, it has posted a “Frequently Asked Questions” (FAQ) document in response to a number of requests from parties who hold short interests in restricted stock (the “Dividend Short Holders”) of Scilex Holding Company (Nasdaq: SCLX, “Scilex”) regarding its previously announced elective offering of restricted stock of Scilex (the “Offering”).]]>https://www.globenewswire.com/news-release/2023/07/05/2699555/0/en/Sorrento-Announces-Positive-Phase-IIa-Study-Results-of-Abivertinib-for-the-Treatment-of-Relapsed-Refractory-Marginal-Zone-Lymphoma-R-R-MZL-and-Its-Plan-for-a-Pivotal-Phase-III-Stud.html?f=22&fvtc=4&fvtv=43606Sorrento Announces Positive Phase IIa Study Results of Abivertinib for the Treatment of Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL) and Its Plan for a Pivotal Phase III Study 2023-07-05T13:00:00Z<![CDATA[SAN DIEGO, July 05, 2023 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (OTC: SRNEQ) today announced positive results from a China phase IIa study of Abivertinib on R/R MZL and its plan for a pivotal study.]]>https://www.globenewswire.com/news-release/2023/06/26/2694495/0/en/Sorrento-Announces-the-Full-Enrollment-of-the-Pivotal-Phase-3-Trial-with-Olgotrelvir-OVYDSOTM-STI-1558-a-Second-Generation-Oral-Mpro-Inhibitor-as-a-Standalone-Treatment-for-COVID-1.html?f=22&fvtc=4&fvtv=43606Sorrento Announces the Full Enrollment of the Pivotal Phase 3 Trial with Olgotrelvir (OVYDSOTM) (STI-1558), a Second Generation Oral Mpro Inhibitor, as a Standalone Treatment for COVID-192023-06-26T13:00:00Z<![CDATA[SAN DIEGO, June 26, 2023 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (OTC: SRNEQ) announced today the full enrollment in a pivotal Phase 3 study of Sorrento’s oral Mpro inhibitor, Ovydso (STI-1558), in mild or moderate symptomatic adults infected with SARS-CoV-2, or COVID-19.]]>https://www.globenewswire.com/news-release/2023/06/13/2687181/0/en/Sorrento-Therapeutics-Inc-announces-a-4-6-Million-U-S-Government-contract-from-the-NIAID-for-a-Sensitive-Reusable-and-Rapid-Diagnostic-Platform-for-Pandemic-Preparedness.html?f=22&fvtc=4&fvtv=43606Sorrento Therapeutics, Inc. announces a $4.6 Million U.S. Government contract from the NIAID for a Sensitive, Reusable, and Rapid Diagnostic Platform for Pandemic Preparedness2023-06-13T13:00:00Z<![CDATA[SAN DIEGO, June 13, 2023 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (OTC: SRNEQ, "Sorrento") today announces it has been awarded a $4.6 million contract from the National Institute of Allergy and Infectious Diseases, a part of the National Institutes of Health (NIH) for the development of in vitro diagnostics for biodefense, antimicrobial resistant infections and emerging infectious diseases. The award shows NIAID’s support for the development of promising quantitative diagnostics technologies for detection of signatures from biothreat pathogens as well as pathogens causing emerging or reemerging infectious diseases, and for pandemic preparedness.]]>https://www.globenewswire.com/news-release/2023/06/05/2682017/0/en/Shanghai-Escugen-Biotechnology-Co-Ltd-a-partner-of-Levena-Biopharma-a-Sorrento-Company-releases-positive-results-from-a-first-in-human-study-of-ESG401-a-TROP2-Antibody-Drug-Conjuga.html?f=22&fvtc=4&fvtv=43606Shanghai Escugen Biotechnology Co., Ltd., a partner of Levena Biopharma, a Sorrento Company, releases positive results from a first-in-human study of ESG401, a TROP2 Antibody Drug Conjugate in patients with locally advanced/metastatic solid tumors at the ASCO 2023 Meeting2023-06-05T13:00:00Z<![CDATA[CHICAGO, June 05, 2023 (GLOBE NEWSWIRE) -- Shanghai Escugen Biotechnology Co., Ltd. (“Escugen”), a partner of Levena (Suzhou) Biopharma Co., Ltd. (“Levena”), a wholly owned subsidiary of Sorrento Therapeutics, Inc. (Sorrento), today released preliminary results from a first-in-human study of ESG401, a trophoblast cell-surface antigen 2 (TROP2) antibody drug conjugate (ADC), in patients with locally advanced/metastatic solid tumors at the 2023 Annual Meeting of ASCO, the American Society of Clinical Oncology, held June 2-6 in Chicago, IL. ESG401 is an innovative ADC developed by Escugen and Levena. Escugen and Levena Biopharma jointly own the domestic and international patents of this ADC and share global rights for the product. ESG401 is composed of a humanized anti-Trop2 IgG1 monoclonal antibody (mAb) conjugated to a topoisomerase I inhibitor SN38 via a proprietary stable covalent linker with a drug antibody ratio (DAR) of 8. ESG401 has potential differentiated advantages over its competitors in terms of safety, effectiveness and process robustness. Using an innovative, highly stable and cleavable linker, this ADC demonstrated that it releases very little free toxin during circulation, which may reduce off target toxicity in a series of preclinical studies. Additionally, premature release of the mAb may compete for binding sites with the ADC to reduce its efficacy. The ADC highly enriches in tumor tissues and rapidly endocytoses, thereby effectively killing tumor cells and inhibiting tumor growth.]]>Sorrento Therapeutics, Inc. Figure 1Sorrento Therapeutics, Inc. Figure 2Sorrento Therapeutics, Inc. Figure 3https://www.globenewswire.com/news-release/2023/02/19/2611046/0/en/Sorrento-Posts-Form-8937-to-Supplement-its-Previously-Issued-FAQ-Regarding-the-Dividend-of-Scilex-Holding-Company-Common-Stock-Nasdaq-SCLX-Scilex.html?f=22&fvtc=4&fvtv=43606Sorrento Posts Form 8937 to Supplement its Previously Issued “FAQ” Regarding the Dividend of Scilex Holding Company Common Stock (Nasdaq: SCLX, “Scilex”)2023-02-19T01:37:09Z<![CDATA[SAN DIEGO, Feb. 18, 2023 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today posted an IRS Form 8937 (the “Form 8937”) to supplement its previously issued “Frequently Asked Questions” document under the “Investors” section of its website at www.sorrentotherapeutics.com regarding its recent dividend to Sorrento stockholders of shares of common stock of Scilex Holding Company (“Scilex”) previously held by Sorrento.]]>https://www.globenewswire.com/news-release/2023/02/17/2610955/0/en/Sorrento-Issues-Update-to-its-Previously-Issued-FAQ-Regarding-the-Dividend-of-Scilex-Holding-Company-Common-Stock-Nasdaq-SCLX-Scilex.html?f=22&fvtc=4&fvtv=43606Sorrento Issues Update to its Previously Issued “FAQ” Regarding the Dividend of Scilex Holding Company Common Stock (Nasdaq: SCLX, “Scilex”)2023-02-17T20:47:36Z<![CDATA[SAN DIEGO, Feb. 17, 2023 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today posted an update to its previously issued “Frequently Asked Questions” document under the “Investors” section of its website at www.sorrentotherapeutics.com regarding its recent dividend to Sorrento stockholders of shares of common stock of Scilex Holding Company previously held by Sorrento (the “Dividend Stock”).]]>https://www.globenewswire.com/news-release/2023/02/13/2607082/0/en/Joint-Statement-by-Sorrento-Therapeutics-Inc-and-Scilex-Holding-Company-on-Today-s-Isolated-Chapter-11-Filing-By-Sorrento-Therapeutics-Inc.html?f=22&fvtc=4&fvtv=43606Joint Statement by Sorrento Therapeutics, Inc. and Scilex Holding Company on Today’s Isolated Chapter 11 Filing By Sorrento Therapeutics, Inc.2023-02-13T20:46:49Z<![CDATA[SAN DIEGO and PALO ALTO, Calif., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) and an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, together with Sorrento, issued the following statements:]]>